This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Vapotherm Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 0/6

Vapotherm şirketinin toplam hissedar öz sermayesi $-81.3M ve toplam borcu $118.4M olup, bu da borç-öz sermaye oranını -145.6% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $67.9M ve $149.2M dir.

Anahtar bilgiler

-145.6%

Borç/özkaynak oranı

US$118.41m

Borç

Faiz karşılama oranı	n/a
Nakit	US$2.90m
Eşitlik	-US$81.32m
Toplam yükümlülükler	US$149.25m
Toplam varlıklar	US$67.93m

Son finansal sağlık güncellemeleri

Recent updates

Vapotherm announces $23M private placement

Feb 08

Vapotherm GAAP EPS of -$0.98 misses by $0.20, revenue of $13.5M misses by $3.02M

Nov 02

Vapotherm draws downgrade at William Blair after 2Q results

Aug 04

Vapotherm: Out Of Air

May 11

Is Vapotherm (NYSE:VAPO) Using Too Much Debt?

Jan 24

Vapotherm: Hardly Breathing Room

Jul 11

Health Check: How Prudently Does Vapotherm (NYSE:VAPO) Use Debt?

May 10

Vapotherm reports Q1 results

May 05

The Independent Director of Vapotherm, Inc. (NYSE:VAPO), Anthony Arnerich, Just Bought 59% More Shares

Mar 12

Announcing: Vapotherm (NYSE:VAPO) Stock Increased An Energizing 225% In The Last Year

Mar 11

Does Vapotherm (NYSE:VAPO) Have A Healthy Balance Sheet?

Jan 19

Vapotherm guides Q4 revenue above consensus, ~212% Y/Y growth

Jan 13

Thomas Smith of Vapotherm, Inc. (NYSE:VAPO) Just Spent US$217k On Shares

Dec 14

Investors Who Bought Vapotherm (NYSE:VAPO) Shares A Year Ago Are Now Up 132%

Dec 11

Vapotherm shares +9% on higher Q4 guidance

Dec 01

Vapotherm: The Game Has Completely Changed

Nov 13

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: VAPO negatif hissedar özkaynağı var; bu, kısa vadeli varlıkların kısa vadeli yükümlülükleri karşılamamasından daha ciddi bir durumdur.

Uzun Vadeli Yükümlülükler: VAPO şirketinin negatif özkaynağı bulunmaktadır; bu, kısa vadeli varlıkların uzun vadeli yükümlülükleri karşılamamasından daha ciddi bir durumdur.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: VAPO negatif hissedar özkaynağı var ki bu yüksek borç seviyesinden daha ciddi bir durumdur.

Borcun Azaltılması: VAPO 'in negatif özkaynağı var, dolayısıyla borcunun zaman içinde azalıp azalmadığını kontrol etmemize gerek yok.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: VAPO şirketinin mevcut serbest nakit akışına göre bir yıldan az nakit akışı süresi bulunmaktadır.

Tahmini Nakit Akışı: VAPO un, serbest nakit akışı her yıl % 1.7 oranında tarihi oranda azalmaya devam ederse bir yıldan az nakit akışı süresi vardır

This company has been acquired

Vapotherm Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 0/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

The New York Stock Exchange to Commence Delisting Proceedings against Vapotherm

Vapotherm Receives Price Cure Notification Letter from the NYSE Indicates its Stock Price Above the NYSE's Minimum Requirement

Vapotherm Announces NYSE Continued Listing Standard Notice

Is Vapotherm (NYSE:VAPO) Using Too Much Debt?

Health Check: How Prudently Does Vapotherm (NYSE:VAPO) Use Debt?

Does Vapotherm (NYSE:VAPO) Have A Healthy Balance Sheet?

Recent updates

Perceptive Discovery Fund LP, managed by Perceptive Advisors LLC completed the acquisition of Vapotherm, Inc. (OTCPK:VAPO) from a group of shareholders.

Perceptive Discovery Fund LP, managed by Perceptive Advisors LLC entered into definitive merger agreement to acquire Vapotherm, Inc. (OTCPK:VAPO) for $15.1 million.

Vapotherm, Inc. to Unveil Access365 Home Ventilation Solution at MEDTRADE

The New York Stock Exchange to Commence Delisting Proceedings against Vapotherm

Vapotherm, Inc. Revises Revenue Guidance for the Full Year 2023

Vapotherm, Inc. to Report Q3, 2023 Results on Nov 08, 2023

Vapotherm Announces Presentation of an Investigator-Initiated Clinical Trial, 'High Flow Humidified Oxygen as an Early Intervention in Children with Acute Severe Asthma - a Feasibility Randomized Controlled Trial' at the European Respiratory Society International Congress 2023

Vapotherm, Inc. Revises Earnings Guidance for Fiscal 2023

Vapotherm, Inc. to Report Q2, 2023 Results on Aug 08, 2023

Vapotherm, Inc. Reports Impairment of Long-Lived and Intangible Assets for the First Quarter Ended March 31, 2023

Vapotherm Receives Price Cure Notification Letter from the NYSE Indicates its Stock Price Above the NYSE's Minimum Requirement

Vapotherm, Inc. to Report Q4, 2022 Results on Feb 23, 2023

Vapotherm announces $23M private placement

Vapotherm, Inc. Provides Revenue Guidance for the Fourth Quarter of 2022

Vapotherm, Inc. Provides Revenue Guidance for 2022

Vapotherm GAAP EPS of -$0.98 misses by $0.20, revenue of $13.5M misses by $3.02M

Vapotherm, Inc. to Report Q3, 2022 Results on Nov 02, 2022

Vapotherm Announces NYSE Continued Listing Standard Notice

Vapotherm draws downgrade at William Blair after 2Q results

Vapotherm, Inc. Reports Unaudited Condensed Consolidated Impairment Charges for the Second Quarter Ended June 30, 2022

Vapotherm, Inc. to Report Q2, 2022 Results on Aug 03, 2022

Vapotherm, Inc. Plans to Move All of Its Manufacturing Operations from New Hampshire to Mexico

Price target decreased to US$4.83

Vapotherm, Inc.(NYSE:VAPO) dropped from Russell 2000 Growth Index

Vapotherm: Out Of Air

Vapotherm, Inc. Revises Earnings Guidance for the Fiscal Year 2022

Vapotherm, Inc., Annual General Meeting, Jun 21, 2022

Vapotherm, Inc. Provides Revenue Guidance for the First Quarter of 2022

Consensus forecasts updated

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Price target decreased to US$34.33

Vapotherm, Inc. Provides Consolidated Earnings Guidance for the Fiscal Year 2022

Vapotherm, Inc. to Report Q4, 2021 Results on Feb 24, 2022

Is Vapotherm (NYSE:VAPO) Using Too Much Debt?

Vapotherm, Inc. Announces Revenue Guidance for the Fourth Quarter of 2021, Full Year 2021 and 2022

Third quarter 2021 earnings released: US$0.52 loss per share (vs US$0.49 loss in 3Q 2020)

Chief Accounting Officer Joel Dube has left the company

Vapotherm, Inc. Revises Revenue Guidance for the Fiscal Year 2021

Vapotherm, Inc. Announces FDA 510(k) Clearance for HVT 2.0 Next Generation Platform

Senior VP notifies of intention to sell stock

Second quarter 2021 earnings released: US$0.67 loss per share (vs US$0.35 loss in 2Q 2020)

Senior VP & Chief Commercial Officer exercised options and sold US$170k worth of stock

Vapotherm: Hardly Breathing Room

Insider recently bought US$4.8m worth of stock

Independent Director Marina Hahn has left the company

Independent Chairman of the Board recently bought US$170k worth of stock

Health Check: How Prudently Does Vapotherm (NYSE:VAPO) Use Debt?

First quarter 2021 earnings released: US$0.40 loss per share (vs US$0.66 loss in 1Q 2020)

Vapotherm, Inc. Provides Financial Guidance for 2021

Vapotherm reports Q1 results

The Independent Director of Vapotherm, Inc. (NYSE:VAPO), Anthony Arnerich, Just Bought 59% More Shares

Independent Director recently bought US$109k worth of stock

Announcing: Vapotherm (NYSE:VAPO) Stock Increased An Energizing 225% In The Last Year

Full year 2020 earnings released: US$2.16 loss per share (vs US$2.74 loss in FY 2019)

Revenue and earnings beat expectations

New 90-day low: US$23.17

Vapotherm, Inc. to Report Q4, 2020 Results on Feb 24, 2021

Senior VP & Chief Commercial Officer notifies of intention to sell stock

Senior VP & Chief Commercial Officer exercised options and sold US$56k worth of stock

Does Vapotherm (NYSE:VAPO) Have A Healthy Balance Sheet?

Vapotherm guides Q4 revenue above consensus, ~212% Y/Y growth

New 90-day high: US$32.08

Thomas Smith of Vapotherm, Inc. (NYSE:VAPO) Just Spent US$217k On Shares

Insider recently bought US$217k worth of stock

Investors Who Bought Vapotherm (NYSE:VAPO) Shares A Year Ago Are Now Up 132%

Analysts update estimates

Vapotherm, Inc. Revises Revenue Guidance for the Fourth Quarter and Full Year 2020

Vapotherm shares +9% on higher Q4 guidance